Clinical trial · Observational
Prognostic Value of Body Composition in Lung Cancer
Prognostic Value of Body Composition in Therapy-Naïve Patients With Non-Small Cell Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The effect of body composition on the survival rate is one of the research topics of interest in cancer patients and gaining attention in the last years. Body mass index is often used a proxy measure of total adiposity and previous studies examining the relationship between BMI and cancer outcomes have been showed distinct results . Obese patients with malignancies such as colorectal, breast, and pancreatic cancers, have been shown to have a worse prognosis than normal-weight patients . Nevertheless, obese patients with non small cell lung cancer(NSCLC) have been observed to have a better clinical outcome than normal/low-weight cancer patients . In this study, we examined the effects of subcutaneous adipose tissue, visceral adipose tissue and skeletal muscle volumes on survival in metastatic NSCLC patients under different treatment regimens. Since there is no standard method for adipose tissue measurement, we evaluated the abdominal cavity with multi-slice and single-slice computed tomography measurements.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Body Composition and Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| measured of body composition with computed tomography | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Stage-IV non small cell lung cancer (NSCLC)
- description
- Eighty-three patients with stage-IV NSCLC who received at least one cycle of platinum based chemotherapy (PBCT) or tyrosine kinase inhibitor (TKI) therapy and who underwent pre treatment fluorodeoxyglucose (FDG)-positron emission tomography (PET) /computed tomography (FDG PET/CT) from June 2012 to February 2019
- interventionNames
- Other: measured of body composition with computed tomography
Primary outcomes (3)
- measure
- To evaluate the impact of visceral adipose tissue (VAT) on the prognosis of metastatic non-small cell lung cancer (NSCLC) patients.
- timeFrame
- through study completion, an average of 6 months
- description
- Visceral adipose tissue (VAT) area was measured by using computed tomography (CT). The entire abdominopelvic region from the "diaphragm dome" to the "symphysis pubis" level was determined as the study area. The volume was recorded as cm3. Index values were calculated by proportioning VAT to body surface area (BSA) and median index value was determined. The survival rates of patients with an index value greater and less than the mean index value were compared.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Having a pathological diagnosis of non small cell lung cancer 2. Having a stage-IV disease 3. To have received at least one course of treatment 4. Presence of positron emission tomography /computed tomography (PET/CT) examination before treatment and having it taken in our hospital 5. The data about the study can be accessed in our center. 6. To be over 18 years old Exclusion Criteria: 1. Unable to access patients data 2. PET/CT CDs cannot be accessed or are not suitable for evaluation.
References
Publications (0)
Data not yet available